Free An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs February 23, 2024Vol.50 No.08By Alexandria Carolan
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Conversation with The Cancer Letter Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Black History MonthFreeIn the Archives Roderic Pettigrew, founding director of NIBIB, reflects on a career as a “physicianeer”— merging medicine with engineering February 23, 2024Vol.50 No.08By Robert A. Winn and Alexandria Carolan
Black History MonthConversation with The Cancer Letter University of Maryland’s Owonikoko: What it means to be a Black director of an NCI-designated cancer center February 16, 2024Vol.50 No.07By Amy Lacey, Otis W. Brawley and Paul Goldberg
Capitol Hill Delay in passing the FY24 budget is “disastrous for our cancer centers” February 16, 2024Vol.50 No.07By Alexandria Carolan
Guest Editorial Patient navigation, financial toxicity top the agenda as Jill Biden, Kimryn Rathmell visit Atrium Health Wake Forest February 16, 2024Vol.50 No.07By Ruben A. Mesa
Guest Editorial SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing February 16, 2024Vol.50 No.07By Virginia Kaklamani, Srivani Ravoori and Carlos L. Arteaga
NCI Kimryn Rathmell: Flat funding in FY24 would mean more cuts to NCI programsNew NCI director to continue the National Cancer Plan set in motion by predecessor Monica Bertagnolli February 09, 2024Vol.50 No.06By Alexandria Carolan
